The use of recombinant factor VIIa for bleeding in paediatric practice.
Summary. Recombinant factor VIIa is licensed for use in patients with haemophilia and inhibitors. More recently it has been used as an unlicensed product in adults for the treatment of life threatening bleeding. However, its use in paediatric practice has been limited. We describe a series of patients from one paediatric centre, where recombinant factor VIIa has been used when conventional treatment has failed to achieve haemostasis.
Millar
C G
CG
Department of Paediatric Haematology, St James University Hospital, Leeds, UK.
Stringer
M D
MD
Sugarman
I
I
Richards
M
M
D000293:Adolescent; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D017809:Fatal Outcome; D006470:Hemorrhage / Q000188:drug therapy* / Q000503:physiopathology; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa